Rashed Dewan
Financieel Directeur/CFO bij PROFOUND MEDICAL CORP.
Vermogen: 190 688 $ op 30-04-2024
Actieve functies van Rashed Dewan
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
PROFOUND MEDICAL CORP. | Financieel Directeur/CFO | 03-03-2022 | - |
Comptroller/Controller/Auditor | 19-05-2021 | 03-03-2022 | |
Human Resources Officer | - | 03-03-2022 | |
Corporate Officer/Principal | 03-05-2018 | 19-05-2021 |
Loopbaan van Rashed Dewan
Eerdere bekende functies van Rashed Dewan
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Profound Medical, Inc.
Profound Medical, Inc. Medical SpecialtiesHealth Technology Profound Medical, Inc. develops and commercializes a unique, minimally invasive treatment for prostate cancer. Its novel technology combines Magnetic Resonance Imaging (MRI) guidance and ultrasound energy to deliver thermal ablative therapy to the prostate gland. The firm deliveres via a trans-urethral approach, the technique combines the image quality of MRI with thermal ultrasound as the treatment tool. Its method of prostate cancer treatment affords highly accurate and precise treatment within the prostate gland in a short time span in an outpatient setting. The company was founded in June 2008 by Michael Bronskill, Rajiv Chopra and Paul Chipperton and is headquartered in Toronto, Canada. | Comptroller/Controller/Auditor | 06-07-2015 | - |
Opleiding van Rashed Dewan
University of Southern California | Undergraduate Degree |
Statistieken
Internationaal
Canada | 3 |
Verenigde Staten | 2 |
Operationeel
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 1 |
Human Resources Officer | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
PROFOUND MEDICAL CORP. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Profound Medical, Inc.
Profound Medical, Inc. Medical SpecialtiesHealth Technology Profound Medical, Inc. develops and commercializes a unique, minimally invasive treatment for prostate cancer. Its novel technology combines Magnetic Resonance Imaging (MRI) guidance and ultrasound energy to deliver thermal ablative therapy to the prostate gland. The firm deliveres via a trans-urethral approach, the technique combines the image quality of MRI with thermal ultrasound as the treatment tool. Its method of prostate cancer treatment affords highly accurate and precise treatment within the prostate gland in a short time span in an outpatient setting. The company was founded in June 2008 by Michael Bronskill, Rajiv Chopra and Paul Chipperton and is headquartered in Toronto, Canada. | Health Technology |
- Beurs
- Insiders
- Rashed Dewan
- Ervaring